Incyte in Portugal
E-mail: encomendas@alloga-logifarma.pt
Web: https://incyte.pt/
Address:
-
Alloga Logifarma
Rua Cláudio Galeno Edifício Alloga, Cabra Figa 2635-154 Rio de Mouro
Phone: +351 21 925 3410
Fax: +351 21 9253429
Other Incyte's locations around the world
Clinical Trials sponsored by Incyte
-
Incyte Biosciences UKVoltooidVersnelde fase chronische myeloïde leukemie | Chronische fase Chronische myeloïde leukemie | Philadelphia-chromosoom-positieve acute lymfoblastische leukemie | Blastische fase chronische myeloïde leukemieVerenigd Koninkrijk, Ierland
-
Incyte BioSciences FranceVoltooidChronische myeloïde leukemieFrankrijk
-
Incyte Biosciences BeneluxVoltooidChronische myeloïde leukemie | CML | Philadelphia-chromosoom-positieve acute lymfoblastische leukemie | Ph+ ALLESBelgië
-
Incyte Biosciences Japan GKWervingDiffuus grootcellig B-cellymfoom | Non Hodgkin lymfoomJapan
-
Incyte Biosciences International SàrlVoltooidGeavanceerde maligniteitenVerenigde Staten
-
Incyte Biosciences International SàrlBeëindigdUitgezaaide kanker | Geavanceerde maligniteitenVerenigde Staten
-
Incyte Biosciences International SàrlVoltooidBaarmoederhalskanker | Hepatocellulair carcinoom | Slokdarmkanker | Eierstokkanker | Mesothelioom | Niet-kleincellige longkanker (NSCLC) | Urotheelcarcinoom | Merkelcelcarcinoom | Diffuus grootcellig B-cellymfoom | Triple-negatieve borstkanker | Niercelcarcinoom (RCC) | Kleincellige longkanker (SCLC) | Plaveiselcelcarcinoom... en andere voorwaardenVerenigde Staten
-
Incyte Biosciences International SàrlIngetrokkenBCR-ABL positieve acute lymfoblastische leukemieDuitsland, Frankrijk, Tsjechië
-
Incyte CorporationWervingHidradenitis suppurativa (HS)Verenigde Staten, Oostenrijk, België, Canada, Duitsland, Polen, Spanje, Australië, Denemarken, Frankrijk, Verenigd Koninkrijk, Japan, Bulgarije, Nederland, Tsjechië, Griekenland, Italië
-
Incyte CorporationWervingNiet-segmentale vitiligoDuitsland, Verenigde Staten, Italië, Polen, Canada, Frankrijk, Bulgarije, Hongarije, Verenigd Koninkrijk
About Incyte
Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. Today, we employ approximately 1500 people and have operations in the U.S., Europe and Japan. Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity. The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.